Stevanato Group S.p.A. Ordinary Shares (STVN)
13.44
-0.66 (-4.68%)
NYSE · Last Trade: Nov 4th, 5:32 PM EST
News & Press Releases
Lost Money on Stevanato Group S.p.A. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 28.57% Stock Decline
Stevanato Group S.p.A. ("Stevanato" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Stevanato Group S.p.A. (NYSE: STVN), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Stevanato Group S.p.A. on November 3, 2026.
By The Law Offices of Frank R. Cruz · Via Business Wire · November 4, 2026
Lost Money on Stevanato Group S.p.A. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 28.57% Share Price Drop
Investors who lost money on Stevanato Group S.p.A. ("Stevanato" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Stevanato Group S.p.A. (NYSE: STVN) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 3, 2026 disclosure regarding Stevanato Group S.p.A.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · November 4, 2026
Did You Lose Money on Stevanato Group S.p.A. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 28.57% Share Price Decline
Investors who suffered losses on Stevanato Group S.p.A. ("Stevanato" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Stevanato Group S.p.A. (NYSE: STVN) investors into whether the Company may have violated the federal securities laws. The investigation comes after a November 3, 2026 disclosure concerning Stevanato Group S.p.A.
By The Law Offices of Howard G. Smith · Via Business Wire · November 4, 2026
Stevanato Group (STVN) Shareholder Investigation Following Stock Decline – Kehoe Law Firm, P.C.
PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Stevanato Group S.p.A. ("Stevanato" or the "Company") (NYSE: STVN) following the Company’s November 3, 2026 disclosures and the resulting decline in its stock price.
By Kehoe Law Firm · Via GlobeNewswire · November 4, 2026
Stevanato Group Q3 Earnings Call Highlightsmarketbeat.com
Stevanato Group (NYSE:STVN) reported third-quarter 2026 revenue growth of 8% to €326.1 million, supported by continued expansion in its biopharmaceutical and diagnostic solutions business despite weaker demand tied to GLP-1 therapies and a decline in its engineering segment.
Chairman and Chief Exec
Via MarketBeat · November 4, 2026
Stevanato (STVN) Q3 2026 Earnings Call Transcriptfool.com
Biologics demand held firm while GLP-1 volumes shape the 2027 outlook.
Via The Motley Fool · November 3, 2026
US Stock Gap Movers: Up and Down Names in Today's Sessionchartmill.com
Via Chartmill · November 3, 2026
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2026.
By Stevanato Group S.p.A. · Via Business Wire · November 3, 2026
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies, with a focus on sensitive biologics and other injectable therapies. The work builds on Aptar Pharma's integrated system-level framework, launched in July 2026, and brings complementary expertise together across the injectable value chain.
By Stevanato Group S.p.A. · Via Business Wire · October 27, 2026
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2026 on Tuesday, November 3, 2026, at 6:30 a.m. (EDT).
By Stevanato Group S.p.A. · Via Business Wire · October 20, 2026
Stevanato Group to Participate in Two Upcoming Investor Conferences
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences:
By Stevanato Group S.p.A. · Via Business Wire · September 8, 2026
Stevanato Group Q2 Earnings Call Highlightsmarketbeat.com
Stevanato Group (NYSE:STVN) reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
R
Via MarketBeat · August 9, 2026
Stevanato (STVN) Q2 2026 Earnings Call Transcriptfool.com
Revenue grew 8% as high-value solutions surged 16%, driving adjusted EBITDA up 21%.
Via The Motley Fool · August 4, 2026
Stevanato Group Q2 2026 Earnings Call: Complete Transcriptbenzinga.com
Stevanato Group (NYSE:STVN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
Via Benzinga · August 4, 2026
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026.
By Stevanato Group S.p.A. · Via Business Wire · August 4, 2026
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders.
By Stevanato Group S.p.A. · Via Business Wire · July 30, 2026
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4, 2026, at 6:30 a.m. (EDT).
By Stevanato Group S.p.A · Via Business Wire · July 21, 2026
2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Nowfool.com
Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.
Via The Motley Fool · June 9, 2026
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs.
By Stevanato Group · Via Business Wire · June 8, 2026
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting
Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders (“Shareholders’ Meeting”) held virtually on May 26, 2026, have passed.
By Stevanato Group S.p.A. · Via Business Wire · June 3, 2026
Stevanato (STVN) Q1 2026 Earnings Transcriptfool.com
Stevanato (STVN) Q1 2026 Earnings Transcript
Via The Motley Fool · May 8, 2026
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026.
By Stevanato Group S.p.A. · Via Business Wire · May 7, 2026
Stevanato Group to Participate in Three Upcoming Investor Conferences
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences:
By Stevanato Group S.p.A. · Via Business Wire · May 4, 2026
Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter 2026 on Thursday, May 7, 2026, at 6:30 a.m. (EDT).
By Stevanato Group · Via Business Wire · April 23, 2026
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Healthcare Forum taking place on Tuesday, March 17 and Wednesday, March 18, 2026.
By Stevanato Group S.p.A. · Via Business Wire · March 12, 2026